A BRAF G469A mutant NSCLC case obtained a deep and durable response after ICIs treatment, which suggested that BRAF non-V600 mutation may benefit more from immunotherapy than EGFR/ALK-driven mutation in NSCLC (73). Here, ALK is linked to non-small cell lung carcinoma.